|The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression|
D Gulei, L Magdo, A Jurj, L Raduly, R Cojocneanu-Petric, A Moldovan, ...
Cell death & disease 9 (2), 1-16, 2018
|SERS-based differential diagnosis between multiple solid malignancies: Breast, colorectal, lung, ovarian and oral cancer|
V Moisoiu, A Stefancu, D Gulei, R Boitor, L Magdo, L Raduly, S Pasca, ...
International journal of nanomedicine 14, 6165, 2019
|Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia|
C Tomuleasa, S Fuji, C Berce, A Onaciu, S Chira, B Petrushev, WT Micu, ...
Frontiers in Immunology 9, 239, 2018
|Role of key micronutrients from nutrigenetic and nutrigenomic perspectives in cancer prevention|
AI Irimie, C Braicu, S Pasca, L Magdo, D Gulei, R Cojocneanu, C Ciocan, ...
Medicina 55 (6), 283, 2019
|Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome|
A Jurj, L Pop, B Petrushev, S Pasca, D Dima, I Frinc, D Deak, ...
Critical Reviews in Clinical Laboratory Sciences 55 (7), 501-515, 2018
|Antiproliferative effects of propofol and lidocaine on the colon adenocarcinoma microenvironment|
T Tat, A Jurj, C Selicean, S Pasca, D Ionescu
J buon 24 (1), 106-115, 2019
|MicroRNA-155 implication in M1 polarization and the impact in inflammatory diseases|
S Pasca, A Jurj, B Petrushev, C Tomuleasa, D Matei
Frontiers in immunology 11, 625, 2020
|LEAM vs. beam vs. CLV conditioning regimen for autologous stem cell transplantation in malignant lymphomas. retrospective comparison of toxicity and efficacy on 222 patients in …|
A Colita, A Colita, H Bumbea, A Croitoru, C Orban, LE Lipan, OG Craciun, ...
Frontiers in Oncology 9, 892, 2019
|KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma|
S Pasca, C Tomuleasa, P Teodorescu, G Ghiaur, D Dima, V Moisoiu, ...
Frontiers in Oncology 9, 1137, 2019
|Targeting the microenvironment in MDS: the final frontier|
P Teodorescu, S Pasca, D Dima, C Tomuleasa, G Ghiaur
Frontiers in Pharmacology 11, 1044, 2020
|Minimal residual disease in chronic lymphocytic leukemia: a consensus paper that presents the clinical impact of the presently available laboratory approaches|
C Tomuleasa, C Selicean, S Cismas, A Jurj, M Marian, D Dima, S Pasca, ...
Critical reviews in clinical laboratory sciences 55 (5), 329-345, 2018
|Approach to the adult acute lymphoblastic leukemia patient|
V Sas, V Moisoiu, P Teodorescu, S Tranca, L Pop, S Iluta, S Pasca, ...
Journal of Clinical Medicine 8 (8), 1175, 2019
|A narrative review of central nervous system involvement in acute leukemias|
D Deak, N Gorcea-Andronic, V Sas, P Teodorescu, C Constantinescu, ...
Annals of Translational Medicine 9 (1), 2021
|Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?|
C Constantinescu, S Pasca, T Tat, P Teodorescu, C Vlad, S Iluta, D Dima, ...
Journal for ImmunoTherapy of Cancer 8 (1), 2020
|Persistent basophilia may suggest an “accelerated phase” in the evolution of CALR-positive primary myelofibrosis toward acute myeloid leukemia|
J Dobrowolski, S Pasca, P Teodorescu, C Selicean, I Rus, M Zdrenghea, ...
Frontiers in Oncology 9, 872, 2019
|Clinical approach to the patient in critical state following immunotherapy and/or stem cell transplantation: guideline for the on-call physician|
C Constantinescu, C Bodolea, S Pasca, P Teodorescu, D Dima, I Rus, ...
Journal of Clinical Medicine 8 (6), 884, 2019
|Medical application of hydrogen in hematological diseases|
L Qian, Z Wu, J Cen, S Pasca, C Tomuleasa
Oxidative medicine and cellular longevity 2019, 2019
|Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis|
D Matei, R Craciun, D Crisan, B Procopet, T Mocan, S Pasca, R Zaharie, ...
Journal of Clinical Medicine 10 (16), 3688, 2021
|Day 15 and day 33 minimal residual disease assessment for acute lymphoblastic leukemia patients treated according to the BFM ALL IC 2009 protocol: Single-center experience of …|
LE Radu, A Colita, S Pasca, C Tomuleasa, C Popa, C Serban, ...
Frontiers in oncology 10, 923, 2020
|Fibroblast dynamics as an in vitro screening platform for anti‐fibrotic drugs in primary myelofibrosis|
C Tomuleasa, S Selicean, G Gafencu, B Petrushev, L Pop, C Berce, A Jurj, ...
Journal of Cellular Physiology 233 (1), 422-433, 2018